White Rose University Consortium logo
University of Leeds logo University of Sheffield logo York University logo

Immunisation with recombinant polymorphic membrane protein D elicits robust protection against sexually transmitted Chlamydia trachomatis infection

Paes, William Neville Wayne (2015) Immunisation with recombinant polymorphic membrane protein D elicits robust protection against sexually transmitted Chlamydia trachomatis infection. PhD thesis, University of York.

William Paes - 107037664 - PhD Thesis - Final Version.pdf
Available under License Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 UK: England & Wales.

Download (12Mb) | Preview


Chlamydia trachomatis (Ct) is the most common sexually transmitted bacterial pathogen worldwide, responsible for ~90 million new cases of disease each year, with asymptomatic infections giving rise to sequelae such as pelvic inflammatory disease, ectopic pregnancy and infertility in women. Aggressive ‘seek and treat’ public health measures have not stemmed the rise of Ct infections, leading to proposal of the ‘arrested immunity’ hypothesis, where herd immunity within a population is blunted following earlier treatment with antibiotics. This suggests vaccination as the next key step in potentially eliminating Ct infections. Due to the paucity of robust clinical data, protective immune parameters have largely been derived from studies in mice, where pathogen-specific Th1-type immunity involving CD4+ T cells has been the focus of preclinical vaccine development. Our study represents the first preclinical characterization of a novel, rationally designed second-generation lipid adjuvant (SLA) in combination with the highly conserved recombinant Ct polymorphic membrane protein D (rPmpD) antigen. We demonstrate robust protection against urogenital Ct infection in the C57BL/6 murine model, characterized by significantly enhanced resistance to infection and reduction in mean bacterial load. However, enhanced Th1-type immunity was not found to correlate with relative protection, which rather coincided with the presence of robust rPmpD-specific serum and cervico-vaginal IgG titres. Prior to our study, the only convincing evidence of neutralizing antibodies effecting protection against chlamydial infection in vivo has emerged from studies employing the antigenically variable Ct MOMP as a vaccine immunogen. We propose that anti-rPmpD antibodies may play a significant role in vaccine-induced protection against urogenital Ct challenge, and that the role of antibodies warrants further investigation in future Ct vaccine development.

Item Type: Thesis (PhD)
Related URLs:
Academic Units: The University of York > Biology (York)
Identification Number/EthosID: uk.bl.ethos.680616
Depositing User: Mr William Neville Wayne Paes
Date Deposited: 29 Feb 2016 11:44
Last Modified: 08 Sep 2016 13:33
URI: http://etheses.whiterose.ac.uk/id/eprint/11896

You do not need to contact us to get a copy of this thesis. Please use the 'Download' link(s) above to get a copy.
You can contact us about this thesis. If you need to make a general enquiry, please see the Contact us page.

Actions (repository staff only: login required)